{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:47:00Z","timestamp":1794559620855,"version":"4.9.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:00:00Z","timestamp":1511222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Aegerion Pharmaceuticals"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Danone Research"},{"name":"Sanofi\/Genzyme"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004349","name":"BASF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004349","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Aegerion Pharmaceuticals"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Danone Research"},{"name":"Sanofi\/Genzyme"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004349","name":"BASF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004349","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hoffmann LaRoche"},{"name":"MSD"},{"name":"Sanofi. D.A."},{"name":"Sanofi and Regeneron Pharmaceuticals, Inc"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.atherosclerosis.2017.11.020","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:01:44Z","timestamp":1511222504000},"page":"99-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany"],"prefix":"10.1016","volume":"268","author":[{"given":"Winfried","family":"M\u00e4rz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz-Werner","family":"Dippel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlheinz","family":"Theobald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Gorcyca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eerban R.","family":"Iorga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib1","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1093\/eurheartj\/ehw334","article-title":"Cardiovascular disease in Europe: epidemiological update 2016","volume":"37","author":"Townsend","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib2","series-title":"Noncommunicables Disease (NCS) Country Profiles: Germany","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib3","series-title":"N.\u00a0European Cardiovascular Disease Statistics 2017","author":"Wilkins","year":"2017"},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib4","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib9","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.clinthera.2017.03.001","article-title":"Use of lipid-modifying therapy and LDL-C goal attainment in a high-cardiovascular-risk population in The Netherlands","volume":"49","author":"Kuiper","year":"2017","journal-title":"Clin. Ther."},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib11","doi-asserted-by":"crossref","first-page":"e013255","DOI":"10.1136\/bmjopen-2016-013255","article-title":"Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines","volume":"7","author":"Steen","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib12","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.dib.2016.09.037","article-title":"Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world","volume":"9","author":"Gitt","year":"2016","journal-title":"Data Brief"},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib13","first-page":"15","article-title":"The impact of lipid-lowering treatment patterns on LDL-C reduction and goal attainment in secondary prevention in Germany","volume":"2","author":"Rajagopalan","year":"2006","journal-title":"Prev. Cont."},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1006\/pmed.2002.1050","article-title":"Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns","volume":"35","author":"Ruof","year":"2002","journal-title":"Prev. Med."},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib15","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the european society of Cardiology (ESC) and the european Atherosclerosis society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib16","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40256-016-0179-y","article-title":"LDL-Cholesterol: standards of treatment 2016: a German perspective","volume":"16","author":"M\u00e4rz","year":"2016","journal-title":"Am. J. Cardiovasc Drugs"},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.atherosclerosis.2016.05.037","volume":"252","author":"Piepoli","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib19","first-page":"120","article-title":"Good practice of secondary data analysis (GPS): guidelines and recommendations","volume":"77","author":"Swart","year":"2015","journal-title":"Gesundheitswesen"},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/clc.22641","article-title":"Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and\/or diabetes mellitus in 2014: insights from a large US managed-care population","volume":"40","author":"Steen","year":"2017","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib21","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1093\/eurheartj\/eht309.3689","article-title":"Impact of a budget-restrictive (Germany) versus an incentive-driven (UK) reimbursement system on LDL-goal-achievement in statin-treated patients for secondary prevention: results of DYSIS","volume":"34","author":"Gitt","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00392-016-0991-z","article-title":"Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk","volume":"105","author":"Laufs","year":"2016","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib23","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib24","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bmj.39609.449676.25","article-title":"Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2","volume":"336","author":"Hippisley-Cox","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib25","first-page":"223","article-title":"Chronic kidney disease in primary care in Germany","volume":"25","author":"Gergei","year":"2017","journal-title":"J.\u00a0Public Health"},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.09.004","article-title":"Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients","volume":"255","author":"Gitt","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/ijcp.12315","article-title":"Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS)","volume":"68","author":"Devroey","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.atherosclerosis.2017.11.020_bib28","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.atherosclerosis.2016.07.001","article-title":"Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: an analysis of more than 33,000 high cardiovascular risk patients in Japan","volume":"251","author":"Teramoto","year":"2016","journal-title":"Atherosclerosis"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017313904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915017313904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:23:06Z","timestamp":1762186986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915017313904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":28,"alternative-id":["S0021915017313904"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.11.020","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}